# OnCo record nct06459180 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06459180/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06459180", "NCT06459180" ;
  schema:name "A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With"@en ;
  schema:alternateName "TroFuse-020"@en ;
  schema:description "A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Tisotumab vedotin in cervical cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06459180/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06459180> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-07-24" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/tisotumab-vedotin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/merck/> .